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OBJECTIVE—Diabetic neuropathy is manifested either by loss of
nociception (painless syndrome) or by mechanical hyperalgesia and
tactile allodynia (pain in response to nonpainful stimuli). While
therapies with vasodilators or neurotrophins reverse some func-
tional and metabolic abnormalities in diabetic nerves, they only
partially ameliorate neuropathic pain. The reported link between
nociception and targets of the anti-inﬂammatory drug sulfasalazine
prompted us to investigate its effect on neuropathic pain in diabetes.
RESEARCH DESIGN AND METHODS—We examined the
effects of sulfasalazine, salicylates, and the poly(ADP-ribose) poly-
merase-1 inhibitor PJ34 on altered nociception in streptozotocin-
induced diabetic rats. We also evaluated the levels of sulfasalazine
targets in sciatic nerves and dorsal root ganglia (DRG) of treated
animals. Finally, we analyzed the development of tactile allodynia in
diabetic mice lacking expression of the sulfasalazine target nuclear
factor-B (NF-B) p50.
RESULTS—Sulfasalazine completely blocked the development of
tactile allodynia in diabetic rats, whereas relatively minor effects
were observed with other salicylates and PJ34. Along with the
behavioral ﬁndings, sciatic nerves and DRG from sulfasalazine-
treated diabetic rats displayed a decrease in NF-B p50 expression
compared with untreated diabetic animals. Importantly, the
absence of tactile allodynia in diabetic NF-B p50
/ mice
supported a role for NF-B in diabetic neuropathy. Sulfasala-
zine treatment also increased inosine levels in sciatic nerves
of diabetic rats.
CONCLUSIONS—The complete inhibition of tactile allodynia in
experimental diabetes by sulfasalazine may stem from its ability to
regulate both NF-B and inosine. Sulfasalazine might be useful in
the treatment of nociceptive alterations in diabetic patients.
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D
istal symmetric sensory neuropathy is a com-
mon complication of diabetes. Diabetic patients
can suffer from either a painless syndrome,
with loss of sensation to touch, pain, or temper-
ature, or a painful disorder characterized by mechanical
hyperalgesia and allodynia (i.e., pain in response to non-
painful stimuli), depending on the type of nerve ﬁbers
being affected. Experimental models of the disease exhibit
responses similar to those present in patients, including a
decrease in mechanical nociceptive thresholds, enhanced
action potential, and alterations in second messengers (1).
The mechanisms underlying abnormal nociception in
diabetes are unclear. Although therapies with neuro-
trophins or vasodilators reverse some functional and
metabolic abnormalities in diabetic nerves, they only
partially ameliorate abnormal pain perception (2,3). These
ﬁndings suggest that other pathways contribute to en-
hanced nociception in diabetes.
Sulfasalazine is a sulfonamide and aminosalicylate con-
jugate long used in the treatment of inﬂammatory condi-
tions, such as inﬂammatory bowel disease and rheumatoid
arthritis. Approximately one-third of orally administered
sulfasalazine is absorbed in the intestine, with the rest
being cleaved by enteric bacteria into 5-aminosalicyic acid
and sulfapyridine. In vitro and in vivo studies suggest that
several mechanisms may contribute to the anti-inﬂamma-
tory action of sulfasalazine. These include inhibition of
nuclear factor-B (NF-B) activity (4–6); enhanced re-
lease of adenosine (7,8); inhibition of superoxide, leuko-
trienes, and thromboxane B2 production in leukocytes
(9–11); and inhibition of secretory phospholipase A2 re-
lease (12).
The reported link between nociception and some of the
mediators of the anti-inﬂammatory action of sulfasalazine,
such as NF-B and adenosine, prompted us to investigate
the effects of sulfasalazine on neuropathic pain in experi-
mental diabetes. We report that administration of sul-
fasalazine completely blocks the development of tactile
allodynia in diabetic rats.
RESEARCH DESIGN AND METHODS
Induction of diabetes. Diabetes was induced in Lewis rats (weighing 200
g, fasted overnight) by a single intraperitoneal injection of streptozotocin (60
mg/kg body wt). After 48 h, body weight and blood levels of glucose and GHb
were monitored regularly and also at the time of death. Insulin was adminis-
tered as needed to maintain body weight but without preventing chronic
hyperglycemia. Animals exhibiting poor health or blood glucose levels 250
mg/dl were excluded. Diabetic rats were randomly divided in groups of 8–10
animals and received sulfasalazine (0.6 mg/ml drinking water, equivalent to
100 mg  kg body wt
1  day
1), sodium salicylate or aspirin (0.3 g/kg diet,
equivalent to 30 mg  kg body wt
1  day
1), and the poly(ADP-ribose)
polymerase-1 (PARP-1) inhibitor PJ34 (0.3 g/kg diet, equivalent to 25 mg  kg
body wt
1  day
1). The doses of sulfasalazine, salicylates, and PJ34 inhibitor
were based on previous studies on inﬂammation and diabetic retinopathy
(6–8,13). Treatment of diabetic rats was initiated 6–10 days after injection of
streptozotocin and continued for 3–9 months. A group of normal rats was also
treated with the same dose of sulfasalazine for 9 weeks. To determine the
amount of drug consumed, drinking water was changed and measured every
other day, and food was changed and measured weekly.
Diabetes was also induced in mice lacking expression of NF-B p105
(precursor of the NF-B p50 subunit) (The Jackson Laboratories; Bar Harbor,
ME), referred to as NF-B p50
/ in the text, and in their normal wild-type
counterparts (B6129PF2/J mice). NF-B p50
/ mice are viable, appear to
develop normally, and exhibit unimpaired development of their immune
system (14). Diabetes was induced in NF-B p50
/ mice by a daily intraperi-
toneal injection of streptozotocin (60 mg/kg body wt) for 5 consecutive days.
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were monitored regularly.
Behavioral studies
Tactile allodynia. This test was performed as described previously (15)
using a series of six Von Frey ﬁlaments (Stoelting, Chicago, IL) with
logarithmically increasing stiffness (1.4–15 g for rats and 0.4–6.0 g for mice).
The test was considered completed when four measurements were made after
the initial change in behavior or after ﬁve consecutive negative scores. The
resulting sequence of positive and negative scores was used to calculate the
force at which there is 50% probability of withdrawal (50% withdrawal
threshold) (16). The test was performed on at least six to eight rats per group.
Two evaluations per animal (right and left paws) were averaged; the mean 
SE of the individual responses in the six to eight animals was considered the
50% withdrawal threshold for each group. Diabetic rats and mice exhibited
tactile allodynia as reﬂected by 50% withdrawal thresholds 8 and 2.5 g,
respectively. The statistical signiﬁcance of the differences among groups was
analyzed by the Kruskal-Wallis nonparametric test. Where signiﬁcance was
observed, multiple comparisons between groups were analyzed by the Dunn’s
test.
Paw pressure-withdrawal test. The Randall and Selitto test was performed
as described previously (15). The nociceptive ﬂexion reﬂex was evaluated in
four to eight rats per group using a Basile analgesymeter (Stoelting). Four
readings per animal were taken at 5-min intervals and subsequently averaged;
the mean  SE of the individual responses was considered the threshold for
each group. Signiﬁcant differences between normal and diabetic rats were
analyzed by ANOVA followed by Dunnett’s test.
Preparation of fractions and immunoblotting analysis. Nuclear-enriched
and cytosolic fractions were prepared from sciatic nerves and dorsal root
ganglia (DRG) (pooled L4-L6) using a commercial kit (Panomics, Redwood
City, CA). Brieﬂy, desheathed sciatic nerves and DRG were homogenized at
4°C in a glass-glass homogenizer in 0.4 and 0.15 ml, respectively, of 10 mmol/l
HEPES, pH 7.9; 10 mmol/l KCl; 10 mmol/l EDTA; 1 mmol/l dithiothreitol
(DTT); and 0.4% IGEPAL supplemented with 1 complete protease and
phosphatase inhibitor cocktails (included in the kit). After a 10-min incubation
on ice, samples were centrifuged at 15,000  g for 5 min. The supernatants
(cytosolic fractions) were removed, and pellets were resuspended in 100 l2 0
mmol/l HEPES, pH 7.9; 400 mmol/l NaCl; 1 mmol/l EDTA; 10% glycerol; and 1
mmol/l DTT, supplemented with protease and phosphatase inhibitors on a
rocking platform for2ha t4°C, followed by centrifugation for 5 min at
15,000  g. The supernatants from this second centrifugation (nuclear-
enriched fractions) and the cytosolic fractions were stored at 80°C. Protein
concentration was measured by a modiﬁed Lowry assay. The purity of
nuclear-enriched fractions was conﬁrmed by immunoblotting using antibodies
against the cytosolic proteins calpain 2 and phospho-Akt (Cell Signaling,
Danvers, MA).
Samples of 10–20 g protein were subjected to SDS-PAGE (11% gels) and
transferred onto polyvinylidene ﬂuoride membranes (NEN, Boston, MA) at 0.3
A for 1 h. Membranes were blocked with 5% milk in Tris-HCl–buffered saline
plus 0.05% Tween-20 (blocking solution) and incubated 1–2 h at room
temperature with goat anti–NF-B p50, rabbit anti–NF-B p65 (Santa Cruz
Biotechnology, Santa Cruz, CA), or mouse anti–phospho-p65 NF-B (Cell
Signaling) (1:200, 1:750, and 1:1,000, respectively). After incubation for 45 min
at room temperature with horseradish peroxidase–conjugated secondary
antibodies, blots were developed with enhanced chemiluminescence sub-
strate (Perkin Elmer, Boston, MA). Immunoreactivity was quantiﬁed by
densitometry and compared with the extracellular signal–regulated kinase 2
(ERK2) signal in each sample to correct for differences in protein loading.
Assay of adenosine/adenosine metabolites
Reverse-phase high-performance liquid chromatography. Desheathed
sciatic nerves from normal, diabetic, and sulfasalazine-treated diabetic rats
were homogenized in cold 5% perchloric acid followed by centrifugation at
14,000  g for 5 min. Deproteinized supernatants were neutralized with
potassium bicarbonate and subjected to reverse-phase high-performance
liquid chromatography (HPLC) on Alltech C18 Adsorbosphere columns as
described previously (17). Samples were eluted at 1.3 ml/min with a methanol
gradient formed by mixing buffer A (0.1 mol/l KH2PO4, pH 6) and buffer B (0.1
mol/l KH2PO4, pH 6, and 15% methanol). The elution protocol was 0–4 min
with 100% buffer A, 4–8 min with 30% buffer A and 70% buffer B, 8–25 min with
100% buffer B, and 25–35 min with 100% buffer A. Absorbance was measured
at 260 nm. This method resolves ATP, ADP, AMP, adenosine, and inosine
standards. Under these conditions, we did not detect an adenosine peak in the
sciatic nerve extracts, but we observed two large peaks corresponding to AMP
and inosine and two smaller peaks corresponding to ATP and ADP.
Tandem mass spectrometry. Sciatic nerves were homogenized in 10
mmol/l sodium phosphate, pH 7.2, followed by freeze/thawing and centrifu-
gation at 14,000  g. Homogenates were ﬁltered thorough 10-kDa cutoff
centrifugal ﬁlters, and 10 l ultraﬁltrates was injected. The extracts were
assayed by liquid chromatography–tandem mass spectrometry using 2695
Separation Module (Atlantis dC-18 column; 2.1  50 mm, 3 m; Waters,
Milford, MA) with a Micromass Quattro Micro triple quadrupole mass spec-
trometer (Waters MicroMass, Manchester, U.K.). Mobile phase was 26 mmol/l
ammonium formate, pH 3.8 (solvent A), and 90% acetonitrile in water (solvent
B) (Burdick & Jackson, Muskegon, MI) in gradient: 0–10 min with 100–95% A,
10–11 min with 95–40% A, 11–20 min with 40% A, 20–21 min with 40–100% A,
and 21–30 min with 100% A. Flow rate was 0.2 ml/min. Adenosine (tR  6.4
min) and inosine (tR  3.2 min) were detected by electronspray positive
ionization–mass spectrometric multiple reaction monitoring. Adenosine was
monitored for m/z 268.08 parent ion and m/z 136.1 fragment ion, and inosine
was monitored for m/z 269.08 parent ion and m/z 137.1 fragment ion.
RESULTS
Effect of experimental treatments on physiological
parameters. Streptozotocin-induced diabetic rats, either
untreated or subjected to any of the experimental treat-
ments, exhibited signiﬁcantly lower body weights than
their age-matched normal controls (Table 1). Similarly,
blood glucose and GHb for diabetic rats and diabetic rats
treated with sulfasalazine, other salicylates, or PJ34 were
signiﬁcantly elevated compared with the normal controls
throughout the study periods (Table 1).
Sulfasalazine treatment completely prevents devel-
opment of tactile allodynia in diabetic rats. Consistent
with previous observations (18), experimentally diabetic
rats exhibited signs of tactile allodynia (i.e., pain in
response to nonpainful, low-intensity stimuli) 4–7 days
after streptozotocin injection, as evidenced by a signiﬁcant
decrease in the 50% withdrawal thresholds to von Frey
ﬁlaments (0 time in Fig. 1A). The tactile allodynia in the
diabetic animals persisted during the 9-month experimen-
tal period. Importantly, treatment with sulfasalazine com-
pletely blocked the development of tactile allodynia in
diabetic rats (Fig. 1A). The effectiveness of sulfasalazine
was also evident when the percentage of animals exhibit-
ing a 50% withdrawal threshold higher than a reference
TABLE 1
Therapies with sulfasalazine, salicylates, or PJ34 do not normal-
ize the alterations in body weight, blood glucose, and GHb levels
in experimentally diabetic rats
Body wt
(g)
Blood
glucose
(mg/dl) GHb (%)
9 months
Normal 609  58 76  11 4.0  0.2
Diabetic 304  48* 325  30* 9.0  1.1*
Diabetic 	
sulfasalazine 300  36* 344  1* 9.9  0.7*
3 months (experiment 1)
Normal 449  20 109  12 3.7  0.1
Diabetic 267  31* 281  43* 9.1  1.2*
Diabetic 	
sulfasalazine 263  30* 314  25* 7.7  1.3*
Diabetic 	 sodium
salicylate 269  29* 299  23* 7.6  0.5*
Diabetic 	 buffered
aspirin 257  24* 314  33* 8.1  1.1*
3 months (experiment 2)
Normal 458  14 122  1 3.8  0.2
Diabetic 276  42* 291  39* 9.2  0.9*
Diabetic 	
sulfasalazine 256  18* 293  1* 9.2  2.0*
Diabetic 	 PJ34 263  28* 287  61* 9.2  1.1*
Data are means  SD of 6–10 animals. *Signiﬁcantly different from
normal rats at P  0.01 (ANOVA followed by Dunnett’s test).
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observed in 50% of the diabetic rats after 1 month and in
100% after 3 months of therapy. We compared the effect of
sulfasalazine on diabetic tactile allodynia with those of
other salicylates and the PARP-1 inhibitor PJ34. In con-
trast to sulfasalazine treatment, administration of sodium
salicylate, acetylsalicylic acid, or PJ34 only resulted in a
partial, statistically nonsigniﬁcant, amelioration of tactile
allodynia (Fig. 1B). The higher effectiveness of sulfasala-
zine was also evident when the percentage of animals
exhibiting a 50% withdrawal threshold 
8 g was calcu-
lated: responsiveness was observed in 90% of diabetic rats
treated for 3 months with sulfasalazine compared with
only 38, 38, and 25% of those treated with sodium salicy-
late, acetylsalicylic acid, or PJ34, respectively. Interest-
ingly, although daily insulin administration to 4-month
diabetic rats for 4 months corrected the rate of body
weight gain and GHb levels, it only partially ameliorated
tactile allodynia (Table 2).
Sulfasalazine treatment partially ameliorates me-
chanical hyperalgesia in diabetic rats. Experimentally
diabetic rats also developed mechanical hyperalgesia (ev-
idenced by a 50% decrease in the withdrawal thresholds
to mechanical stimuli) as early as 2 weeks after induction
of the disease. In contrast to the complete inhibition of
tactile allodynia, treatment with sulfasalazine for either 6
or 9 months only resulted in a modest amelioration of
mechanical thresholds in diabetic rats that did not reach
statistical signiﬁcance (Table 3). Treatment of diabetic
rats with PJ34 for 9 months was ineffective (Table 3).
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FIG. 1. Sulfasalazine prevents the development of tactile allodynia in
experimentally diabetic rats. A: Experimental diabetes in Lewis rats was
induced by a single injection of streptozotocin as described in RESEARCH
DESIGN AND METHODS. Diabetic rats (D) exhibited early signs of allodynia
4–7 days after streptozotocin injection, as indicated by the values shown
at 0 time (representative of an independent evaluation of two separate
sets comprising a total of 52 diabetic and 16 normal rats). Streptozotocin-
induced diabetic rats were either left untreated or subjected to treatment
with sulfasalazine (starting 6–10 days after streptozotocin injection) for
up to 9 months (DSFZ). B: Streptozotocin-induced diabetic animals
were treated for 3 months with sulfasalazine, sodium salicylate (SAL),
acetylsalicylic acid (aspirin), or PJ34. The presence of tactile allodynia
was investigated at different time points (A) or after 3 months (B)b y
comparison with responses in normal animals (N) (n  6–8 animals per
group were used). Results are means  SE of the averages of the 50%
withdrawal thresholds measured on the left and right paw of each animal
(see RESEARCH DESIGN AND METHODS). Signiﬁcantly different from diabetic
animals at *P < 0.05 and **P < 0.01. ††Signiﬁcantly different from normal
animals at P < 0.01, as calculated by Kruskal-Wallis’ test followed by
Dunn’s test.
TABLE 2
Tight glucose control in 4-month diabetic rats normalizes the rate of body weight gain and GHb levels but only partially ameliorates
tactile allodynia
Body wt (g) GHb (%)
50% Withdrawal
thresholds (g)
Normal/8 months 535  46 3.7  0.1 13.80  2.03
Poor glucose control–diabetic/8 months 270  28* 9.5  0.7* 3.04  0.9†
Poor glucose control–diabetic/4 months (before insulin
treatment) 308  39 9.9  1.6 2.92  0.89
Tight glucose control–diabetic/4 months (after insulin treatment) 403  44‡ 4.9  0.2‡ 6.76  1.46†§
Data are means  SD of 6–10 animals. Four-month diabetic rats (poor glucose control–diabetic/4 months) were either left untreated for an
additional 4 months (poor glucose control–diabetic/8 months) or subjected to tight glucose control for 4 months (tight glucose control–diabetic/4
months). The presence of tactile allodynia was evaluated as indicated in the legend to Fig. 1. *Signiﬁcantly different from normal rats at P  0.01
(Student’s t test). ‡Signiﬁcantly different from poor glucose control–diabetic/4 months at P  0.01 (paired Student’s t test). Signiﬁcantly different
from †normal and §poor glucose control–diabetic/4 months at P  0.01 (Kruskal-Wallis test, followed by Dunn’s test).
TABLE 3
Effects of sulfasalazine and PJ34 on mechanical hyperalgesia in
experimentally diabetic rats
Mechanical hyperalgesia
withdrawal threshold (g)
6 months 9 months
Normal 218  50 198  4
Diabetic 71  3* 87  7*
Diabetic 	 sulfasalazine 111  14* 133  34
Diabetic 	 PJ34 ND 63  5*
Data are means  SE of four to eight animals. *Signiﬁcantly different
from normal rats at P  0.01 (ANOVA, followed by Dunnett’s test).
The statistical analysis showed no signiﬁcant differences when
comparing the diabetic 	 sulfasalazine or diabetic 	 PJ34 with the
untreated diabetic rats; however, the diabetic 	 sulfasalazine with-
drawal thresholds at 9 months were not signiﬁcantly different than
those in normal rats. ND, not determined.
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candidate targets of sulfasalazine that may mediate its ben-
eﬁcial effects on tactile allodynia in experimentally diabetic
rats. In particular, we analyzed changes in levels of NF-B, a
transcription factor proposed to mediate the anti-inﬂamma-
tory actions of sulfasalazine (4–6), and adenosine, a nucleo-
side known to act as an analgesic agonist. We focused on two
initial sites of processing of sensory information in the
peripheral nervous system (PNS): sciatic nerves and DRG.
The sciatic nerves include axons, Schwann cells, and endo-
thelial cells, whereas the DRGs comprise sensory neurons,
satellite, and endothelial cells.
Changes in levels of NF-B subunits in diabetic rats.
We examined the steady-state levels of NF-B subunits in
nuclear-enriched fractions of sciatic nerves and DRG.
Although the expression of NF-B p50 was similar in
sciatic nerves and DRG from normal and diabetic rats, a
signiﬁcant decrease was observed after sulfasalazine treat-
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FIG. 2. Expression of NF-B p50, phospho-p65 (P-p65), and p65 subunits in nuclear-enriched fractions (NEF) of sciatic nerves from normal (N),
3-month diabetic (D), and sulfasalazine-treated 3-month diabetic (S) rats. A: Immunoreactivity of sciatic nerve nuclear-enriched fractions from three
individual animals in each group. Blots were also incubated with anti-ERK2 to control for differences in sample loading. Numbers at the left of each
panel depict the position of molecular mass markers (in kDa). B: Speciﬁcity of the signals was conﬁrmed by immunoblotting of sciatic nerve extracts
with dilutions of anti–NF-B p50 or anti–NF-B p65 antisera previously incubated in the presence (P) or absence () of immunogenic peptides. C:
Densitometry of immunoreactivity of NF-B subunits relative to ERK2 for all animals analyzed in each group (n  5–7) (Signiﬁcantly different from
**normal and
∧∧ untreated diabetics at P < 0.01 as calculated by ANOVA followed by Dunnett’s test).
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FIG. 3. Expression of NF-B subunits in nuclear-enriched fractions (NEF) of DRG from normal (N), 3-month diabetic (D), and sulfasalazine-
treated 3-month diabetic (S) rats. A: Blots show the immunoreactivity in samples from three individual animals in each group. Blots were also
incubated with anti-ERK2 to control for differences in sample loading. B: Densitometry of immunoreactivity of NF-B subunits relative to ERK2
for all the animals analyzed in each group (n  5–7). (Signiﬁcantly different from **normal and
∧∧ untreated diabetics at P < 0.01 as calculated
by ANOVA followed by Dunnett’s test).
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NF-B p65. Sciatic nerve extracts from diabetic rats dis-
played increased levels of NF-B p65 when compared with
normal samples that were corrected by sulfasalazine treat-
ment (Fig. 2). In contrast, diabetic DRG displayed a 30%
decrease in NF-B p65 compared with normal samples
that was not signiﬁcantly altered after treatment with
sulfasalazine (Fig. 3). Finally, a similar pattern, decreased
levels in diabetic compared with normal samples that were
not corrected by sulfasalazine treatment, was observed for
NF-B phospho-p65 (P-p65) in sciatic nerves and DRG
nuclear-enriched fractions (Figs. 2 and 3).
We also performed a control experiment and subjected
normal rats to treatment with sulfasalazine. This treatment
did not signiﬁcantly change levels of NF-B subunits in
nuclear-enriched fractions of sciatic nerves and DRG.
Densitometry of sciatic nerve nuclear-enriched fractions
showed that NF-B p50 and p65 levels (relative to ERK2)
were 1.00  0.11 and 1.04  0.05 (normal rats) and 1.06 
0.18 and 1.01  0.17 (sulfasalazine-treated normal rats),
respectively. Levels of NF-B p50 and p65 in DRG nuclear-
enriched fractions were 0.94  0.07 and 1.49  0.04
(normal rats) and 0.81  0.11 and 1.33  0.12 (sulfasala-
zine-treated normal rats), respectively (means  SE, n 
4; nonsigniﬁcant differences by Student’s t test).
Diabetic NF-B p50
/ mice do not develop tactile
allodynia. We also analyzed the role of NF-Bi nt h e
development of enhanced nociception in experimental
diabetes using NF-B p50
/ mice. To this end, we com-
pared the development of tactile allodynia by experimen-
tal diabetes in wild-type (B6129PF2/J) and NF-B p50
/
mice. Blood glucose and GHb levels in diabetic wild-type
and NF-B p50
/ mice were signiﬁcantly higher than in
their normal counterparts (Table 4). As expected, 6-month
diabetic wild-type mice developed tactile allodynia com-
pared with the normal controls (Table 5). Signiﬁcantly,
normal and diabetic NF-B p50
/ mice displayed with-
drawal thresholds similar to those of normal wild-type
mice (Table 5).
Sulfasalazine treatment increases inosine levels in
sciatic nerves of diabetic rats. To determine whether
the beneﬁcial effects of sulfasalazine might be also medi-
ated through changes in levels of adenosine or its metab-
olites, we analyzed sciatic nerve extracts from normal,
diabetic, and sulfasalazine-treated diabetic rats. Reverse-
phase HPLC showed that sciatic nerve extracts contain
signiﬁcant amounts of inosine, an adenosine deamination
metabolite, whereas signiﬁcant levels of the precursor
nucleoside were not detected. The presence of low levels
of adenosine in sciatic nerve extracts is consistent with its
metabolism to AMP and/or with high adenosine deaminase
activity causing degradation to inosine and other break-
down products. Although levels of inosine in normal and
diabetic nerves were similar, extracts from sulfasalazine-
treated diabetic rats displayed a signiﬁcant increase in this
nucleoside (Table 6). The presence of inosine in sciatic
nerve extracts, together with relatively minor adenosine
peaks (10–40 times smaller than those corresponding to
inosine), was also detected by tandem mass spectrometry
(not shown). However, the small magnitude of the aden-
osine peaks detected by liquid chromatography–tandem
mass spectrometry prevented quantitative analysis among
the different experimental groups.
DISCUSSION
Herein, we demonstrate that administration of sulfasala-
zine to experimentally diabetic rats completely inhibits the
development of tactile allodynia observed in untreated
diabetic animals. The protective effect of this salicylate
conjugate was observed within 1 month after the start of
treatment and persisted throughout the entire study period
(9 months). The complete inhibition of tactile allodynia by
sulfasalazine in diabetic rats contrasted with the partial
effects observed with other salicylates or the PARP-1
inhibitor PJ34 (Fig. 1).
Recent studies support the role of oxidative and nitro-
sative stress in the pathogenesis of some of the alterations
that characterize diabetic neuropathy. Treatment with
inhibitors of PARP-1, an enzyme sensitive to oxidative and
nitrosative stress, normalizes deﬁcits in nerve blood ﬂow,
conduction velocity, and energy metabolism in experimen-
tal diabetes but only partially ameliorates sensory nerve
function (19–21). This is consistent with our observation
that the PARP-1 inhibitor PJ34 does not signiﬁcantly
prevent the development of tactile allodynia (Fig. 1B)o r
mechanical hyperalgesia (Table 3) in experimentally dia-
TABLE 4
Body weight, blood glucose, and GHb levels in normal and
diabetic wild-type and NF-B p50
/ mice
Body wt
(g)
Blood
glucose
(mg/dl) GHb (%)
B6129PF2/J wild type
Normal 36.0  12.0 126  14 3.0  0.2
Diabetic 30.0  3.0* 327  41† 10.9  1.1†
NF-B p50
/
Normal 27.8  5.8 135  22 3.0  0.2
Diabetic 26.4  3.8 299  24† 9.4  0.8†
Data are means  SD of 8–9 wild-type and 18–19 knockout mice.
Measurements were performed 6 months after induction of experi-
mental diabetes. Signiﬁcantly different from normal rats at *P  0.05
and †P  0.01 (Student’s t test).
TABLE 5
Diabetic NF-B p50
/ mice do not develop tactile allodynia
50% Withdrawal threshold (g)
B6129PF2/J
wild-type mice
NF-B p50
/
mice
Normal 5.93  0.21 4.54  1.59
Diabetic 0.84  0.46* 5.59  0.66
Data are means  SD of 8–9 wild-type and 18–19 knockout mice.
Behavioral measurements were performed 6 months after induction
of experimental diabetes. *Signiﬁcantly different from normal mice
at P  0.01 (Kruskal-Wallis test, followed by Dunn’s test).
TABLE 6
Sulfasalazine treatment increases inosine levels in sciatic nerve
extracts of diabetic rats
Rats Inosine (nmol/mg protein)
Normal 3.92  0.47
Diabetic 3.98  0.38
Sulfasalazine-treated diabetic 5.25  0.64*
Data are means  SD of extracts from three to ﬁve animals analyzed
by reverse-phase HPLC. Assays were performed 9 months after
induction of experimental diabetes. *Signiﬁcantly different from
normal and diabetic rats at P  0.05 (ANOVA, followed by Dunnett’s
test).
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with therapies aimed at reducing oxidative stress and its
downstream effectors in peripheral nerves might not be
sufﬁcient to normalize enhanced pain perception in
chronic diabetes. This inference is further supported by
the observation that normalizing glycemia in 4-month
experimentally diabetic rats by daily insulin injection does
not completely reverse tactile allodynia (Table 2). There-
fore, factors other than oxidative stress might contribute
to the development of this diabetes complication.
We observed that tactile allodynia develops rapidly
(4–7 days) after induction of experimental diabetes in
rats by a single streptozotocin injection, in agreement with
previous observations (18). This rapid progression is sim-
ilar to that observed in the reduction of nerve blood ﬂow
and precedes the onset of other alterations, such as
reduction in motor nerve conduction velocity and sciatic
nerve Na
	/K
	 ATPase activity, which develop 2 and 4
weeks, respectively, after induction of diabetes (22). The
rapid development of tactile allodynia indicates that this
complication is independent of long-term structural
changes and other metabolic and functional alterations
that develop more slowly. The absence of tactile allodynia
in experimentally diabetic rats treated with sulfasalazine
starting 6–10 days after the streptozotocin injection, when
a signiﬁcant number of diabetic animals already exhibit
nociceptive alterations (0 time in Fig. 1), indicates that the
therapy not only prevents but reverses these changes.
Nonetheless, additional studies will be required to assess
whether sulfasalazine treatment can also improve alter-
ations resulting from long-term (3–4 months) experimen-
tal diabetes.
The different effectiveness of sulfasalazine treatment on
tactile allodynia and mechanical hyperalgesia in diabetic
rats (complete prevention versus partial amelioration,
respectively) is of interest. As discussed above, tactile
allodynia develops quickly after streptozotocin injection
and appears to involve a mechanism different to that
underlying mechanical hyperalgesia (23). This different
effectiveness of sulfasalazine may reﬂect its speciﬁc tar-
geting of sensory ﬁbers mediating tactile allodynia (i.e.,
large A and small myelinated A nociceptive ﬁbers)
and/or additional effects of this drug on other peripheral
nerve abnormalities (e.g., decreased blood ﬂow). The
different effectiveness of sulfasalazine on tactile allodynia
and mechanical hyperalgesia in diabetes is reminiscent of
the effect of interleukin (IL)-6 and is consistent with the
proposal that mechanical hyperalgesia may require the
participation of speciﬁc nerve ﬁbers and/or their informa-
tion processing at the central nervous system (CNS) (24).
We observed that inhibition of tactile allodynia by
sulfasalazine treatment in diabetic rats is associated with
changes in NF-B expression. Although NF-B activation
appears to induce hyperalgesia in some, but not all,
models of inﬂammatory and neuropathic pain (8,25), its
role in diabetic nociceptive alterations remains controver-
sial. Increased activation of NF-B in the nerve micro-
vasculature of diabetic patients and mice appears to
contribute to thermal hypoalgesia (26). In contrast, de-
creased NF-B activation has been observed in DRG of
diabetic rats (27). We observed decreased expression of
NF-B P-p65, with no signiﬁcant changes in NF-B p50, in
diabetic DRG nuclear-enriched fractions (Fig. 3). This
ﬁnding seems consistent with an overall decrease in the
nuclear translocation of activated NF-B (p50/p65 het-
erodimers) in diabetic DRG. On the other hand, the
increase in NF-B p65 detected in diabetic sciatic nerves
might reﬂect a deﬁcit in retrograde axonal transport of this
subunit in diabetes, similar to observations after nerve
crush injury (28), and/or augmented expression in endo-
thelial or Schwann cells. The normalization of NF-B p65
in sciatic nerve nuclear-enriched fractions by sulfasalazine
hints at a possible mechanism underlying the reversal of
tactile allodynia by this drug in diabetic rats.
An important observation in this study is the absence of
tactile allodynia in experimentally diabetic NF-B p50
/
mice (Table 5). This suggests that NF-B p50–containing
complexes are necessary for activation of target genes
contributing to tactile allodynia in experimentally diabetic
mice. The association between prevention of tactile allo-
dynia and decreased levels of NF-B p50 in sciatic nerve
and DRG nuclear-enriched fractions of diabetic rats
treated with sulfasalazine supports this link. Contrary to
the ﬁndings with nerve NF-B p65, however, we did not
observe differences in the overall levels of NF-B p50 in
sciatic nerve or DRG nuclear-enriched fractions of normal
and diabetic rats, which argues against this subunit con-
tributing to altered nociception in diabetes. It is possible,
however, that opposite changes in the expression of
NF-B p50 in different cells of the PNS (i.e., small,
medium, and large neurons and satellite and endothelial
cells) may result in overall normal levels of this subunit in
diabetic nerves and DRG. Clearly, immunocytochemical
studies will be required to address the localization and
changes in the expression of NF-B subunits in the differ-
ent cells or compartments of diabetic sciatic nerves and
DRG.
Activation of NF-B is critical for neuronal survival,
Schwann cell differentiation, and myelination in peripheral
nerves during development (29). In contrast, after spinal
cord injury, selective inhibition of astroglial NF-B confers
a protective effect through upregulation of IL-6 and down-
regulation of transforming growth factor-2, CXCL10, and
CCL2 (30). These ﬁndings are consistent with the beneﬁ-
cial effects of IL-6 on several parameters of diabetic
neuropathy (24). It is then possible that the beneﬁcial
effects of sulfasalazine therapy on tactile allodynia in
diabetic rats may stem from NF-B–dependent changes in
the expression of cytokines in speciﬁc cell types of DRG
and nerve. This hypothesis is consistent with the observa-
tion that sulfasalazine treatment inhibits both the induc-
tion of inﬂammatory mediators and the formation of
retinal vasculature lesions in diabetic rats (6).
We also addressed whether the nociceptive improve-
ment in sulfasalazine-treated diabetic rats could be medi-
ated by changes in adenosine levels. This was suggested
by the observation that sulfasalazine increases the release
of adenosine both in vivo and in vitro (8) and by the
improved nerve function and analgesia observed in exper-
imentally diabetic rats treated with adenosine or adeno-
sine kinase inhibitors (31,32). We observed that sciatic
nerves contain signiﬁcant levels of inosine, a nucleoside
derived from adenosine deamination, and low levels of the
precursor nucleoside. Both adenosine and inosine are
important neuromodulators. Adenosine, which increases
after nerve injury, induces analgesia through activation of
adenosine A1 receptors (33,34). Inosine, on the other
hand, induces neurite outgrowth in retinal ganglion cells
and cortical neurons (35,36) and is a potent agonist for
A1/A3 adenosine receptors (37). Although inosine levels in
normal and diabetic nerve extracts were similar, we
observed a signiﬁcant increase in this nucleoside upon
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that the diabetic derangement impairs the enhanced re-
lease of adenosine/inosine, which is normally associated
with peripheral nerve injury (34), and that sulfasalazine
treatment overcomes this blockade. This suggests that
sulfasalazine may also impede tactile allodynia in diabetic
rats by releasing nucleosides that cause analgesia.
Investigation of additional targets of sulfasalazine, such
as NMDA receptors (38), may provide a more complete
understanding of the bases for the effectiveness of sul-
fasalazine in diabetic neuropathy. Importantly, our exper-
iments focused on sciatic nerves and DRG, initial sites of
sensory information processing in the PNS. Further stud-
ies should examine changes brought about by sulfasala-
zine treatment in the spinal cord, the ﬁrst level of sensory
processing in the CNS.
In summary, the present study demonstrates that sul-
fasalazine treatment completely impedes the development
of tactile allodynia in experimentally diabetic rats. The
effectiveness of sulfasalazine may reﬂect the combined
modulation of levels of NF-B and inosine and other as yet
unidentiﬁed targets. The absence of tactile allodynia in
diabetic NF-B p50
/ mice supports a role for NF-Bi n
the development of nociceptive alterations in experimen-
tal diabetes. These ﬁndings justify further studies to test
the effects of sulfasalazine on altered nociception in
diabetic patients.
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